Cargando…

Medical Cannabis for Older Patients—Treatment Protocol and Initial Results

Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuhasira, Ran, Ron, Addie, Sikorin, Inbal, Novack, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912698/
https://www.ncbi.nlm.nih.gov/pubmed/31683817
http://dx.doi.org/10.3390/jcm8111819
_version_ 1783479518382522368
author Abuhasira, Ran
Ron, Addie
Sikorin, Inbal
Novack, Victor
author_facet Abuhasira, Ran
Ron, Addie
Sikorin, Inbal
Novack, Victor
author_sort Abuhasira, Ran
collection PubMed
description Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for these patients. This article aims to present a pragmatic treatment protocol for medical cannabis in older adults. We followed consecutive patients above 65 years of age prospectively who were treated with medical cannabis from April 2017 to October 2018. The outcomes included treatment adherence, global assessment of efficacy and adverse events after six months of treatment. During the study period, 184 patients began cannabis treatment, 63.6% were female, and the mean age was 81.2 ± 7.5 years (median age-82). After six months of treatment, 58.1% were still using cannabis. Of these patients, 33.6% reported adverse events, the most common of which were dizziness (12.1%) and sleepiness and fatigue (11.2%). Of the respondents, 84.8% reported some degree of improvement in their general condition. Special caution is warranted in older adults due to polypharmacy, pharmacokinetic changes, nervous system impairment, and increased cardiovascular risk. Medical cannabis should still be considered carefully and individually for each patient after a risk-benefit analysis and followed by frequent monitoring for efficacy and adverse events.
format Online
Article
Text
id pubmed-6912698
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69126982020-01-02 Medical Cannabis for Older Patients—Treatment Protocol and Initial Results Abuhasira, Ran Ron, Addie Sikorin, Inbal Novack, Victor J Clin Med Article Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for these patients. This article aims to present a pragmatic treatment protocol for medical cannabis in older adults. We followed consecutive patients above 65 years of age prospectively who were treated with medical cannabis from April 2017 to October 2018. The outcomes included treatment adherence, global assessment of efficacy and adverse events after six months of treatment. During the study period, 184 patients began cannabis treatment, 63.6% were female, and the mean age was 81.2 ± 7.5 years (median age-82). After six months of treatment, 58.1% were still using cannabis. Of these patients, 33.6% reported adverse events, the most common of which were dizziness (12.1%) and sleepiness and fatigue (11.2%). Of the respondents, 84.8% reported some degree of improvement in their general condition. Special caution is warranted in older adults due to polypharmacy, pharmacokinetic changes, nervous system impairment, and increased cardiovascular risk. Medical cannabis should still be considered carefully and individually for each patient after a risk-benefit analysis and followed by frequent monitoring for efficacy and adverse events. MDPI 2019-11-01 /pmc/articles/PMC6912698/ /pubmed/31683817 http://dx.doi.org/10.3390/jcm8111819 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abuhasira, Ran
Ron, Addie
Sikorin, Inbal
Novack, Victor
Medical Cannabis for Older Patients—Treatment Protocol and Initial Results
title Medical Cannabis for Older Patients—Treatment Protocol and Initial Results
title_full Medical Cannabis for Older Patients—Treatment Protocol and Initial Results
title_fullStr Medical Cannabis for Older Patients—Treatment Protocol and Initial Results
title_full_unstemmed Medical Cannabis for Older Patients—Treatment Protocol and Initial Results
title_short Medical Cannabis for Older Patients—Treatment Protocol and Initial Results
title_sort medical cannabis for older patients—treatment protocol and initial results
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912698/
https://www.ncbi.nlm.nih.gov/pubmed/31683817
http://dx.doi.org/10.3390/jcm8111819
work_keys_str_mv AT abuhasiraran medicalcannabisforolderpatientstreatmentprotocolandinitialresults
AT ronaddie medicalcannabisforolderpatientstreatmentprotocolandinitialresults
AT sikorininbal medicalcannabisforolderpatientstreatmentprotocolandinitialresults
AT novackvictor medicalcannabisforolderpatientstreatmentprotocolandinitialresults